AB-1002 in Patients With Class III Heart Failure

Inclusion criteria: * Age \>18 years of age * Chronic non-ischemic cardiomyopathy * LVEF 15% ≤ 30% by transthoracic echocardiography (TTE) within 6 months prior to enrollment * NYHA Class III HF for a minimum of 3 months HF despite appropriate medical therapy (defined below): * Treatment with appropriate HF therapy as tolerated, including, but not limited to: * Beta blocker therapy and angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) or sacubitril/valsartan combination therapy (Entresto) for ≥ 90 days prior to enrollment. May also receive aldosterone antagonist therapy. Doses of the above medications must be stable for ≥ 30 days prior to enrollment; and * Cardiac resynchronization therapy (CRT), if clinically indicated, must have been implanted ≥ 90 days prior to enrollment. Internal cardioverter defibrillator (ICD) must be implanted, if clinically indicated ≥ 30 days prior to enrollment * Females of childbearing potential must use at least one of the following acceptable birth control methods throughout the study and for 6 months after IP administration: * Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum prior to IP administration * Intrauterine device in place for at least 90 days prior to receiving IP * Barrier methods (diaphragm plus spermicide or condom) starting at least 30 days prior to receiving IP * Abstinence (the subject must be willing to remain abstinent from screening …